The AHNAK Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of A-549 lung adenocarcinoma cells with targeted disruption of the AHNAK gene. This polyclonal knockout pool serves as a loss-of-function model to investigate AHNAK??s roles in cytoskeletal organization, cell adhesion, and signal transduction.
The parental A-549 cell line is a widely used model derived from the lung adenocarcinoma of a 58-year-old Caucasian male. These epithelial cells retain characteristics of alveolar type II pneumocytes and are extensively employed in studies of pulmonary surfactant production, lung adenocarcinoma biology, and respiratory epithelial function. The A-549 background is well-characterized and suitable for examining cancer-relevant phenotypes.
AHNAK encodes a large scaffold nucleoprotein that organizes the actin cytoskeleton and modulates cell adhesion, migration, membrane repair, and calcium signaling. Its activity is regulated by upstream signals including TGF??, calcium influx, PKC, and Akt kinase. AHNAK interacts with partners such as Annexin A2, S100A10, dysferlin, actin filaments, and L-type calcium channels. Downstream, AHNAK influences integrin signaling and ERK pathway activation. In the context of the PI3K/Akt and TGF-??/SMAD pathways, AHNAK acts as a signaling integrator linking membrane and cytoskeletal events to transcriptional and migratory responses. Disruption of AHNAK is expected to perturb these molecular interactions and the associated signaling cascades.
In A-549 lung adenocarcinoma cells, AHNAK knockout provides a physiologically relevant platform to dissect its contribution to tumor cell behavior. Given AHNAK??s involvement in actin dynamics and cell adhesion, the knockout model enables analysis of altered migration, invasion, and adhesion properties that are central to cancer metastasis. Furthermore, because A-549 cells are commonly used in epithelial-mesenchymal transition (EMT) and drug resistance studies, the AHNAK polyclonal knockout population can be utilized to explore how loss of this scaffold protein affects responsiveness to TGF??, chemotherapeutic agents, and EMT induction.
Researchers can employ this knockout model in a variety of functional assays, including western blotting to confirm AHNAK depletion, RT-qPCR for transcript verification, immunofluorescence microscopy to visualize actin cytoskeleton reorganization, and migration or invasion assays to assess phenotypic changes. Additional applications encompass cell adhesion assays, flow cytometric analysis of integrin expression, and phospho-signaling profiling to map alterations in AKT, ERK, and SMAD pathways. These polyclonal knockout cells are suitable for lung adenocarcinoma research, cancer cell signaling studies, and drug screening programs. For further information, please contact Ascent Research.
